New clinical study opens to recruit stage 4 metastatic pancreatic cancer patients

Will a new hope with an advanced drug for the treatment of stage 4 metastatic pancreatic cancer patients prove itself in a new study that has just begun?

The drug is called CPI-613 or Devimistat, and it attacks enzymes involved in the cell’s energy production mechanism. If the cell cannot produce energy, it will die.In a new study that has just begun, the inclusion of CPI-613 is considered standard treatment for these patients and plans to recruit 500 patients.

For further reading

To find out if you are suitable for this study or for other advanced drugs to treat metastatic pancreatic cancer, contact us and we will be happy to help.

To check if our service suits your case
We need to talk

Improve therapeutic outcomes, prolong life and quality of life, is our main business.
We support access to and expand cancer treatments beyond the standard of care, with the most advanced and innovative treatment options in the world, personally matching the individual cancer patient’s medical condition and with the support of top tier oncologists.

Article categories

קטגוריות המאמרים

Popular topics